English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduFindings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.
Tag: Acute Myeloid Leukemia
$1.92M NIH Award Fuels Research to Uncover How Key Protein Transport Mechanism Goes Awry in Cancer
The National Institute of General Medical Sciences has awarded Justin Taylor, M.D., a researcher at Sylvester Comprehensive Cancer Center, a five-year grant totaling $1.92 million for his work to better define the role of XPO1 (Exportin-1) in cancer.
Scientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer
Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The models were described in a late-breaking abstract at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
MD Anderson Research Highlights for February 1, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Novel drug combinations and targeted therapies show promise for patients with leukemia
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
MD Anderson Research Highlights for September 28, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.
Albert Einstein Cancer Center Researcher Receives NCI Outstanding Investigator Award to Study Two Deadly Blood Diseases
Ulrich G. Steidl, M.D., Ph.D., co-director of the Blood Cancer Institute and associate director of basic science at the Albert Einstein Cancer Center (AECC), has received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI).
MD Anderson Research Highlights for August 11, 2021
Current advances include insights into anti-tumor responses, a targeted therapy combination for biliary tract cancers, biomarkers that may predict response to DNA damage repair inhibitors, a “virtual biopsy” using artificial intelligence to characterize tumors, new targeted and immunotherapy approaches for pancreatic cancer, understanding the impact of TP53 mutations on acute myeloid leukemia treatments, as well as a new strategy to overcome treatment-resistant KRAS-mutant lung cancer.
MD Anderson Research Highlights for June 16, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) infections.
Scientists identify potential drug candidates for deadly pediatric leukemia
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer.
Study finds risk of leukemia higher than expected in children with Down syndrome
The risk of childhood leukemia among kids with Down syndrome is higher than predicted, according to a new study led by UC Davis and UC San Francisco researchers. Early diagnosis remains critical.
Robin Roberts, Charles Barkley and TNT’s Ernie Johnson Jr. team up to #EndCancer on Feb. 4
An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University of Texas MD Anderson Cancer Center’s A Conversation with a Living Legend event. Robin Roberts, an anchor of “Good Morning America,” will join Emmy Award-winning sportscaster Ernie Johnson Jr. for a virtual fireside chat with a special guest appearance by 11-time NBA All-Star Charles Barkley.
New drug combination shows promise as powerful treatment for AML
Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies.
Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
T Cell Therapy, Gut Microbiome, Tumorigenicity, and More Featured in September 2020 Toxicological Sciences
Toxicological Sciences features leading research in toxicology in the areas of biomarkers, environmental toxicology, and more in the September 2020 issue.
Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer